PLMA_1170x120_5-28-21

West-Ward

Hikma to buy Roxane for $2.65 billion

Hikma to buy Roxane for $2.65 billion

LONDON — Hikma Pharmaceuticals PLC, a fast growing multinational pharmaceutical group, plans to acquire Roxane Laboratories from Boehringer Ingelheim in a deal valued at $2.65 billion. Hikma said the agreement stands to transform its position in the U.S. generic drug market, establishing the company as the sixth-largest generics maker by revenue. The addition of Roxane